<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JCDSA</journal-id><journal-title-group><journal-title>Journal of Cosmetics, Dermatological Sciences and Applications</journal-title></journal-title-group><issn pub-type="epub">2161-4105</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jcdsa.2021.111004</article-id><article-id pub-id-type="publisher-id">JCDSA-107672</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Successful Treatment of Mutinucleate Cell Angiohistiocytoma with Nd:YAG Laser
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Salih</surname><given-names>Mishlab</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Emily</surname><given-names>Avitan-Hersh</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ziad</surname><given-names>Khamaysi</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Technion institute of technology, Haifa, Israel</addr-line></aff><aff id="aff1"><addr-line>Department of Dermatology, Rambam Health Care Campus, Haifa, Israel</addr-line></aff><pub-date pub-type="epub"><day>03</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>38</fpage><lpage>43</lpage><history><date date-type="received"><day>26,</day>	<month>November</month>	<year>2020</year></date><date date-type="rev-recd"><day>8,</day>	<month>March</month>	<year>2021</year>	</date><date date-type="accepted"><day>11,</day>	<month>March</month>	<year>2021</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  A 50-year-old man had noticed the gradual appearance of asymptomatic skin lesions on the dorsal aspects of the hands during the last 3 years. Physical examination revealed clusters of multiple purplish dome-shaped infiltrated papules. Histopathological examination was compatible mutinucleate cell angiohistiocytoma. We treated him with 10,464 nm Nd:YAG laser, after the second session, some of the lesions had disappeared completely while the rest has gained substantial improvement. There were no adverse reactions and no recurrence after two years of follow-up. MCAH is a rare vascular fibrohistiocytic proliferation. No standard of care exists. We believe that Nd:YAG laser should be considered the treatment of choice.
 
</p></abstract><kwd-group><kwd>Mutinucleate Cell Angiohistiocytoma</kwd><kwd> Laser Therapy</kwd><kwd> Nd:YaG-Neodymium-Doped Yttrium Aluminum Garnet</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Mutinucleate cell angiohistiocytoma is a rare, vascular, fibrohistiocytic proliferation [<xref ref-type="bibr" rid="scirp.107672-ref1">1</xref>]. The course tends to be progressive but benign [<xref ref-type="bibr" rid="scirp.107672-ref2">2</xref>]. The tumor presents as asymptomatic grouped red-to-violaceous papules, developing over weeks to months, which have a predilection for the dorsum of hands and lower extremities [<xref ref-type="bibr" rid="scirp.107672-ref2">2</xref>]. However, Localized, multifocal, and generalized variants have been reported [<xref ref-type="bibr" rid="scirp.107672-ref3">3</xref>], the localized variant is most common and best-described. There is a female predominance with a ratio of 3:1 [<xref ref-type="bibr" rid="scirp.107672-ref4">4</xref>]. The etiology is unknown and these lesions arise as a reactive rather than a neoplastic process [<xref ref-type="bibr" rid="scirp.107672-ref4">4</xref>]. Several reports of spontaneous remission further support the reactive hypothesis. Another theory suggests the influence of female hormone, due to the expression of estrogen receptor (ER) on the interstitial and multinucleate cells of the lesions [<xref ref-type="bibr" rid="scirp.107672-ref5">5</xref>]. This theory may also explain why MCAH occurs more frequently in women [<xref ref-type="bibr" rid="scirp.107672-ref5">5</xref>]. There is an a continuous debate whether MCAH represent a histological variant of dermatofibroma [<xref ref-type="bibr" rid="scirp.107672-ref6">6</xref>], as there is a significant histopathologic overlap, thus, the diagnosis requires an experienced pathologist and a careful clinic-pathological correlation. Treatment is not mandatory but may be desired by patients for cosmetic reasons. No standard of care exists. Treatment options include: intralesional corticosteroids, surgical excision, cryotherapy, and lasers (Argon, PDL and CO<sub>2</sub> lasers [<xref ref-type="bibr" rid="scirp.107672-ref7">7</xref>]. These treatments have all shown anecdotal efficacy. Nd:YAG laser offers the combined efficacy of targeting deep seated vessels and limited melanin absorption, which enhances its influence on deep vascular proliferations, with less pigment alterations, respectively. We describe a case of Mutinucleate cell angiohistiocytoma treated with Nd:YAG laser with a satisfactory result and no recurrence after two-year follow up.</p></sec><sec id="s2"><title>2. Case Presentation</title><p>A 50 y/o male dentist with Fitzpatrick skin type IV with no relevant medical history and no family history of similar dermatological conditions reported the gradual appearance of asymptomatic skin lesions on the dorsal aspects of the hands during the last 3 years. There was no preceding trauma. His physical examination (<xref ref-type="fig" rid="fig1">Figure 1</xref>(a)) revealed clusters of multiple purplish dome-shaped infiltrated papules without scale, on dorsa of hands. Histopathological examination of a 4-mm punch biopsy specimen from the dorsal hand showed epidermal acanthosis within the superficial to mid reticular dermis was a proliferation of haphazardly arranged capillaries and small venules with angulated polygonal multinucleate giant cells embedded within a collagenous fibrotic stroma (<xref ref-type="fig" rid="fig2">Figure 2</xref>(a), <xref ref-type="fig" rid="fig2">Figure 2</xref>(b)). A mixed perivascular infiltrate, composed predominantly of lymphocytes was also present. Vascular endothelial cells were highlighted by antibodies against CD31. Additionally, a marker for lymphatic vessels D2-40 and a marker for HHV8 (LANA1) were negative.</p><p>The patient was diagnosed with MCAH given the peculiar clinical and histopathological findings.</p><p>Topical corticosteroids therapy was ineffective. We treated him with 2 monthly sessions of Nd:YAG laser using a 1064 nm Nd:YAG laser (3 mm spot, 240 J/cm<sup>2</sup> and 40 msec), on the dorsa of hands. After the second session, the patient reported subjective improvement in terms of thickness and color and examination revealed the lesions were paler, more flattened and less infiltrated. After the second session, some of the lesions had disappeared completely while the rest has gained substantial improvement (<xref ref-type="fig" rid="fig1">Figure 1</xref>(b)). The patient had a mild discomfort during the treatment. Treatment was stopped after 2 sessions based on the patient’s satisfaction with treatment results. But in the future, more sessions will be considered.</p><p>There were no adverse reactions such as scarring, bleeding after 2 years of follow-up.</p></sec><sec id="s3"><title>3. Discussion</title><p>Mutinucleate cell angiohistiocytoma is a relatively new entity with a few hundred cases reported so far [<xref ref-type="bibr" rid="scirp.107672-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.107672-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.107672-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.107672-ref4">4</xref>]. There is no clear understanding of the etiology of the MCAH [<xref ref-type="bibr" rid="scirp.107672-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.107672-ref6">6</xref>] and it has been categorized as connective tissue disorder or vascular neoplasia in literature. Meanwhile, surgical approach remains as the definitive therapeutic method in MCAH [<xref ref-type="bibr" rid="scirp.107672-ref7">7</xref>]. Laser therapy is reported to result in clinical resolution of the lesions without scarring in comparison with surgical excision [<xref ref-type="bibr" rid="scirp.107672-ref7">7</xref>]. They are difficult to manage due to their number and deep seated location. Previous reports regarding treatment with argon laser are partially supportive of this treatment [<xref ref-type="bibr" rid="scirp.107672-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.107672-ref9">9</xref>] in part because of the depth of penetration of argon laser is only 500 μm to target deep seated MCAH lesions in the mid or deep reticular dermis. In such cases, as in our case, pre-treatment biopsy showed proliferation of vessels in the papillary and mid dermis with moderate degree of dermal fibrosis. In another report of treatment using PDL in a patient with a 5-year history of multiple MCAH papules on the thighs and calves had merely shown mild improvement, these lesions showed slight vascular proliferation and dermal fibrosis before treatment [<xref ref-type="bibr" rid="scirp.107672-ref10">10</xref>].</p><p>Kopera et al. [<xref ref-type="bibr" rid="scirp.107672-ref7">7</xref>] reported the successful use of the argon laser to treat 2 patients with a 2- to 3-year history of MCAH. Lesions were located on the face and hands. Increased vascularity in the mid dermis with normal epidermis was noticed. Dermal fibrosis was not reported. Laser treatment yielded flattening of the lesions with no scarring at 8 weeks and no recurrence after 1 year. However, Coco et al. [<xref ref-type="bibr" rid="scirp.107672-ref9">9</xref>] reported on a patient with a 5-year history of multiple papules on the lower extremities. Lesions showed proliferation of vessels in the papillary and mid dermis with moderate degree of dermal fibrosis. Treatment with argon laser was unsuccessful. In addition, IPL laser has been reported as a definitive treatment in 2 cases [<xref ref-type="bibr" rid="scirp.107672-ref11">11</xref>]. Lesions appeared as papules on the nose and back with a 3-year history in 1 case. Lesions in either case had increased vascularity without fibrosis. Complete resolution was achieved in both cases, with residual hyperpigmentation reported in 1 case. V&#228;kev&#228; et al. [<xref ref-type="bibr" rid="scirp.107672-ref12">12</xref>] reported treatment of 2 cases of MCAH with the CO<sub>2</sub> laser. These lesions were present for 6 months to a year and showed increased vascularity in papillary and mid dermis with slight hyperkeratosis in the epidermis and sparse fibrohistiocytic cell infiltration. No relapse was noted at 2.5- or 5-month follow-up.</p><p>Whereas Argon laser, PDL, and IPL specifically target the increased superficial vascular component in MCAH lesions, without much influence on the fibrous stroma or the ablation of deep seated vascular proliferations, A deeply penetrating vascular-targeting 1064 nm Nd:YAG laser with limited absorption by melanin, enhances the ability to target the deeper vascular lesions, while maintaining a safety profile in our patient with darker skin phenotype. To our knowledge, we are first to describe a patient with MCAH treated with Nd:YAG laser. We obtained satisfactory results for our patient with no recurrence after two-year follow up.</p></sec><sec id="s4"><title>4. Conclusion</title><p>Based on our experience, we believe that Nd:YAG laser should be considered the treatment of choice in patients with mutinucleate cell angiohistiocytoma where other treatment options might cause discomfort, dyspigmentation or scarring complications.</p></sec><sec id="s5"><title>Author Contribution</title><p>All authors participated in patient care, obtained patient history and workup, and wrote the manuscript</p></sec><sec id="s6"><title>Abbreviations</title><p>Nd:YaG, neodymium-doped yttrium aluminum garnet; IPL, intense pulsed light; MCAH, multinucleate cell angiohistiocytoma; PDL, pulsed dye laser.</p></sec><sec id="s7"><title>Informed Consent</title><p>The patient gave informed consent.</p></sec><sec id="s8"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s9"><title>Cite this paper</title><p>Mishlab, S., Avitan-Hersh, E. and Khamaysi, Z. (2021) Successful Treatment of Mutinucleate Cell Angiohistiocytoma with Nd:YAG Laser. Journal of Cosmetics, Dermatological Sciences and Applications, 11, 38-43. https://doi.org/10.4236/jcdsa.2021.111004</p></sec></body><back><ref-list><title>References</title><ref id="scirp.107672-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Smith, N.P. and Wilson Jones, E. (1985) Multinucleate Cell Angiohistiocytoma: A New Entity. British Journal of Dermatology, 113, 15. https://doi.org/10.1111/j.1365-2133.1985.tb12966.x</mixed-citation></ref><ref id="scirp.107672-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Jaconelli, L., Kanitakis, J., Ktiouet, S., Faure, M. and Claudy, A. (2009) Multinucleate Cell Angiohistiocytoma: Report of Three New Cases and Literature Review. Dermatology Online Journal, 15, 4.</mixed-citation></ref><ref id="scirp.107672-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Frew, J. (2015) Multinucleate Cell Angiohistiocytoma: Clinicopathological Correlation of 142 Cases with Insights into Etiology and Pathogenesis. The American Journal of Dermatopathology, 37, 222-228. https://doi.org/10.1097/DAD.0000000000000075</mixed-citation></ref><ref id="scirp.107672-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Wilson, J.E., Cerio, R. and Smith, N.P. (1990) Multinucleate Cell Angiohistiocytoma: An Acquired Vascular Anomaly to Be Distinguished from Kaposi’s Sarcoma. British Journal of Dermatology, 122, 651-663. https://doi.org/10.1111/j.1365-2133.1990.tb07287.x</mixed-citation></ref><ref id="scirp.107672-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Cesinaro, A.M., Roncati, L. and Maiorana, A. (2010) Estrogen Receptor Alpha Overexpression in Multinucleate Cell Angiohistiocytoma: New Insights into the Pathogenesis of a Reactive Process. The American Journal of Dermatopathology, 32, 655-659. https://doi.org/10.1097/DAD.0b013e3181d3ca49</mixed-citation></ref><ref id="scirp.107672-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Doshi-Chougule, B.N., Gust, A., Mentzel, T. and B&amp;#246;er-Auer, A. (2013) Multinucleate Cell Angiohistiocytoma with Hypertrophic Nerves. Journal of Cutaneous Pathology, 40, 1048-1053. https://doi.org/10.1111/cup.12227</mixed-citation></ref><ref id="scirp.107672-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Kopera, D., Smolle, J. and Kerl, H. (1995) Multinucleate Cell Angiohistiocytoma: Treatment with Argon Laser. British Journal of Dermatology, 133, 308-310. https://doi.org/10.1111/j.1365-2133.1995.tb02636.x</mixed-citation></ref><ref id="scirp.107672-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Sass, U., Noel, J.C., André, J. and Simonart, T. (2000) Multinucleate Cell Angiohistiocytoma: Report of Two Cases with No Evidence of Human Herpesvirus-8 Infection. Journal of Cutaneous Pathology, 27, 258-261. https://doi.org/10.1034/j.1600-0560.2000.027005258.x</mixed-citation></ref><ref id="scirp.107672-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Coco, V., Guerriero, C., Di Stefani, A., Pennacchia, I. and Peris, K. (2016) Linear and Bilateral Multinucleated Cell Angiohistiocytoma (MCAH). Journal of Dermatological Case Reports, 10, 58-61. https://doi.org/10.3315/jdcr.2016.1237</mixed-citation></ref><ref id="scirp.107672-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Applebaum, D.S., Shuja, F., Hicks, L., Cockerell, C. and Hsu, S. (2014) Multinucleate Cell Angiohistiocytoma: A Case Report and Review of the Literature. Dermatology Online Journal, 20, Article ID: 22610.</mixed-citation></ref><ref id="scirp.107672-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Fernández-Jorge, B., del Pozo, J., García-Silva, J., Barja, J.M., Yebra-Pimentel, M.T. and Fonseca, E. (2009) Multinucleate Cell Angiohistiocytoma: Treatment Using Intense Pulsed Light. Dermatologic Surgery, 35, 1141-1143. https://doi.org/10.1111/j.1524-4725.2009.01203.x</mixed-citation></ref><ref id="scirp.107672-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">V&amp;#228;kev&amp;#228;, L., Saksela, O. and Kariniemi, A.L. (2003) Multinucleate Cell Angiohistiocytoma: A Report of Four Cases in Finland. Acta Dermato-Venereologica, 83, 222-223. https://doi.org/10.1080/00015550310007265</mixed-citation></ref></ref-list></back></article>